LifeMD, Inc. (LFMDP)
USD 22.12
(1.28%)
USD 22.12
(1.28%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.21 Million USD | 75.51% |
| 2022 | -39.61 Million USD | 34.83% |
| 2021 | -53.94 Million USD | 14.5% |
| 2020 | -57.48 Million USD | -2163.88% |
| 2019 | -2.55 Million USD | -173.26% |
| 2018 | -1.86 Million USD | 12.45% |
| 2017 | -138.42 Thousand USD | 9.12% |
| 2016 | -1.17 Million USD | -437.69% |
| 2015 | -91.2 Thousand USD | 53.9% |
| 2014 | -416.02 Thousand USD | 3.17% |
| 2013 | -225.1 Thousand USD | -1.32% |
| 2012 | -402.5 Thousand USD | 7.05% |
| 2011 | -442.17 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.07 Million USD | -1664.21% |
| 2024 Q2 | -4.01 Million USD | 1.34% |
| 2023 Q1 | -1.48 Million USD | 22.75% |
| 2023 Q3 | -2.83 Million USD | 15.15% |
| 2023 Q4 | -230.81 Thousand USD | 91.86% |
| 2023 FY | - USD | 75.51% |
| 2023 Q2 | -3.34 Million USD | -125.28% |
| 2022 FY | - USD | 34.83% |
| 2022 Q1 | -12.57 Million USD | -34.96% |
| 2022 Q2 | -12.04 Million USD | 4.23% |
| 2022 Q3 | -5.67 Million USD | 52.86% |
| 2022 Q4 | -1.91 Million USD | 66.19% |
| 2021 Q4 | -9.31 Million USD | 25.31% |
| 2021 Q1 | -11.99 Million USD | 62.9% |
| 2021 Q2 | -15.83 Million USD | -31.98% |
| 2021 Q3 | -12.47 Million USD | 21.19% |
| 2021 FY | - USD | 14.5% |
| 2020 Q4 | -32.32 Million USD | -58.28% |
| 2020 Q1 | -1.65 Million USD | -279.84% |
| 2020 Q2 | -3.12 Million USD | -88.96% |
| 2020 Q3 | -20.42 Million USD | -553.48% |
| 2020 FY | - USD | -2163.88% |
| 2019 Q3 | -889.8 Thousand USD | -18.76% |
| 2019 Q4 | -435.46 Thousand USD | 51.06% |
| 2019 FY | - USD | -173.26% |
| 2019 Q2 | -749.26 Thousand USD | -56.27% |
| 2019 Q1 | -479.46 Thousand USD | -241.47% |
| 2018 Q1 | -279.31 Thousand USD | -44.35% |
| 2018 FY | - USD | 12.45% |
| 2018 Q4 | 338.92 Thousand USD | 183.23% |
| 2018 Q3 | -407.21 Thousand USD | 31.85% |
| 2018 Q2 | -597.49 Thousand USD | -113.91% |
| 2017 Q1 | -374.98 Thousand USD | 47.05% |
| 2017 Q2 | -225.47 Thousand USD | 39.87% |
| 2017 Q4 | -193.5 Thousand USD | 29.27% |
| 2017 FY | - USD | 9.12% |
| 2017 Q3 | -273.56 Thousand USD | -21.33% |
| 2016 Q1 | -105.09 Thousand USD | 61.19% |
| 2016 FY | - USD | -437.69% |
| 2016 Q3 | -207.7 Thousand USD | -35.2% |
| 2016 Q2 | -153.63 Thousand USD | -46.18% |
| 2016 Q4 | -708.25 Thousand USD | -240.99% |
| 2015 FY | - USD | 53.9% |
| 2015 Q4 | -270.82 Thousand USD | -915.68% |
| 2015 Q3 | 33.2 Thousand USD | 1234.72% |
| 2015 Q2 | -2926.00 USD | -113.25% |
| 2015 Q1 | 22.07 Thousand USD | 116.89% |
| 2014 Q1 | -163.39 Thousand USD | 40.05% |
| 2014 Q4 | -130.67 Thousand USD | -10.09% |
| 2014 Q3 | -118.7 Thousand USD | -94.17% |
| 2014 Q2 | -61.13 Thousand USD | 62.59% |
| 2014 FY | - USD | 3.17% |
| 2013 Q3 | -154.42 Thousand USD | -2512.45% |
| 2013 Q2 | -5911.00 USD | 89.55% |
| 2013 Q1 | -56.54 Thousand USD | 48.75% |
| 2013 Q4 | -272.55 Thousand USD | -76.5% |
| 2013 FY | - USD | -1.32% |
| 2012 FY | - USD | 7.05% |
| 2012 Q1 | -21.72 Thousand USD | 0.0% |
| 2012 Q2 | -201.45 Thousand USD | -827.25% |
| 2012 Q3 | -149.54 Thousand USD | 25.77% |
| 2012 Q4 | -110.32 Thousand USD | 26.23% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 62.889% |
| BIMI International Medical Inc. | -15.33 Million USD | 46.447% |
| China Jo-Jo Drugstores, Inc. | 1.22 Million USD | 769.542% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 9.72 Million USD | 184.483% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 9.72 Million USD | 184.483% |
| Leafly Holdings, Inc. | -5.73 Million USD | -43.255% |
| Leafly Holdings, Inc. | -5.73 Million USD | -43.255% |
| LifeMD, Inc. | -8.21 Million USD | -0.0% |
| TRxADE HEALTH, Inc. | -13.72 Million USD | 40.132% |
| PetMed Express, Inc. | -394 Thousand USD | -1984.834% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.927% |